Related Topics

    Pui: News Releases & Feature Stories

    Measuring treatment response proves to be a powerful tool for guiding leukemia treatment

    Measuring the concentration of leukemia cells in patient bone marrow during the first 46 days of chemotherapy helps boost survival of young leukemia patients by better matching patients with the right intensity of chemotherapy. (Ching-Hon Pui, MD)

    Equal access to care helps close survival gap for young African-American cancer patients

    St. Jude Children's Research Hospital closes survival gap for virtually all African-American and white children with cancer in a study that suggests equal access to care translates into an equal chance of a cure. (Dr. Ching-Hon Pui)

    Chemotherapy proves life-saving for some leukemia patients who fail induction therapy

    An international study found that bone marrow transplants are not the best option for some young patients with acute lymphoblastic leukemia (ALL) who fail to attain clinical remission after the initial weeks of intense chemotherapy known as induction therapy. (Dr. Ching-Hon Pui)

    American Society of Clinical Oncology honors Ching-Hon Pui, M.D., for work advancing childhood cancer research and treatment

    St. Jude Children’s Research Hospital physician is the recipient of the 2012 Pediatric Oncology Award.

    Baby, Oh Baby - Camille Davis

    The tiniest patients face the biggest odds when it comes to acute lymphoblastic leukemia. St. Jude clinicians and researchers work to change that scenario.

    Bone marrow transplant survival more than doubles for young high-risk leukemia patients

    St. Jude Children’s Research Hospital investigators reported markedly improved survival of pediatric patients transplanted for high-risk leukemia regardless of donor; cite treatment advances and better donor selection.

    Ching-Hon Pui, M.D., honored by the American Society of Hematology for contributions to childhood cancer treatment

    St. Jude Children’s Research Hospital oncologist Ching-Hon Pui is the recipient of the 2011 Henry M. Stratton Medal for work that has advanced the research and treatment of pediatric leukemia

    Things are looking up for teens with ALL

    St. Jude boosts cure rates for older teens with acute lymphoblastic leukemia.

    Ching-Hon Pui, M.D., recognized with American Association for Cancer Research award

    St. Jude Children’s Research Hospital pediatric oncologist Ching-Hon Pui, M.D., is the recipient of the 2011 Annual AACR Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Research for contributions to childhood cancer research and treatment.

    Intensive chemotherapy can dramatically boost survival of older teenage leukemia patients

    Research led by St. Jude Children’s Research Hospital investigators will likely impact how acute lymphoblastic leukemia is treated in young adults and shows older adolescent age does not dictate worse outcomes against the most common childhood cancer

    Ching-Hon Pui, MD, receives national recognition with Clinical Excellence Award

    Ching-Hon Pui, MD, of St. Jude Children's Research Hospital, is being honored with the Clinical Excellence Award at the fifth annual National Physician of the Year Awards, organized by Castle Connolly Medical Ltd.

    Perilous precursors

    St. Jude scientists identify a completely new and deadly subtype of leukemia that arises from early T-cell precursors. The discovery allows early detection and therapeutic intervention to improve the outcome for children with this form of drug-resistant leukemia.

    Acute lymphoblastic leukemia, the most common childhood cancer, is curable without preventive cranial radiation

    Childhood acute lymphoblastic leukemia (ALL) can be successfully treated using a carefully personalized chemotherapy regimen without cranial radiation, investigators at St. Jude Children's Research Hospital have found. Such radiation of the brain was once a standard ALL treatment to prevent recurrence of the leukemia in the central nervous system (CNS).

    St. Jude Acute Lymphoblastic Leukemia Team recognized with prestigious science award

    Scientists at St. Jude Children’s Research Hospital who represent the interdisciplinary team studying acute lymphoblastic leukemia (ALL) have been recognized by the American Association for Cancer Research (AACR) with the AACR Team Science Award.

    Molecular science could further improve leukemia survival

    The dramatic increase that has occurred in the cure rate for children with acute lymphoblastic leukemia (ALL) will be difficult to replicate in older patients without considerable additional research. In order to raise the survival rate of adolescents and adults with ALL, researchers will need a more thorough understanding of the biology of this form of leukemia, including the role that genes play in therapies.

    Leukemic cells find safe haven in bone marrow

    The cancer drug asparaginase fails to help cure some children with acute lymphoblastic leukemia (ALL) because molecules released by certain cells in the bone marrow counteract the effect of that drug, according to St. Jude investigators.

    Major gene study uncovers secrets of leukemia

    Investigators at St. Jude have discovered previously unsuspected mutations that contribute to the formation of pediatric acute lymphoblastic leukemia, the most common cancer in children.

    Collaboration in China saves lives of children with cancer

    A small pilot program in the People's Republic of China has saved the lives of children who would otherwise have died from acute lymphoblastic leukemia (ALL) because of their family's inability to pay for care.

    St. Jude projects 90 percent cure rate for ALL

    New report from St. Jude suggests that use of gene-based diagnosis and treatment, more effective use of existing drugs and adoption of emerging strategies will continue to boost ALL cure rate.

    Pediatric cancer lacks priority in developing countries

    Partnerships between institutions from developed and underdeveloped countries could improve treatment of children with cancer even in areas of the world that have limited resources, according to St. Jude.

    Giving children access to clinical trials is crucial, Clofarabine approval shows

    Accelerated approval of the drug clofarabine to treat relapsed or refractory pediatric acute lymphoblastic leukemia (ALL) shows the importance of offering children rapid access to new treatments through clinical trials, said investigators at St. Jude.

    Improved ALL treatment may offer hope without radiation

    Improved risk classification for patients with acute lymphoblastic leukemia, more intensive chemotherapy for high risk patients and the use of a drug called dexamethasone, could one day permit physicians to omit irradiation as part of routine treatment.

    Treatment outcome for ALL linked to expression patterns in genes

    A relatively small number of genes are linked to either resistance or sensitivity to four major cancer drugs used to treat acute lymphoblastic leukemia (ALL), suggesting that these genes are key to treatment outcome.

    St. Jude helps South American community improve survival rates for children with leukemia

    The city of Recife, Brazil, experienced a significant improvement in outcome among children treated for acute lymphoblastic leukemia (ALL) during the past decade, even though the community is resource-poor and most patient families are impoverished.

    Molecular analyses of leukemia patients suggest strategies for better treatments

    The cure rate for pediatric acute lymphoblastic leukemia (ALL) may continue to rise with improved use of conventional therapies. But even better therapies based on genetic and pharmacogenetic studies might one day push success rate to 100 percent.

    When it comes to ALL treatment, survival rates for all children soar at St. Jude

    When it comes to ALL treatment, survival rates for all children soar at St. Jude. A St. Jude team found that with equal access to effective therapy, both African-American and white patients could expect high cure rates.

    Good News for ALL Patients

    A new study from St. Jude indicates that survivors of childhood acute lymphoblastic leukemia who have not received radiation treatment as part of their therapy have virtually the same long-term life experiences as the general population.

    Good News for Childhood Leukemia Survivors

    Survivors of childhood acute lymphoblastic leukemia (ALL) who have not received radiation treatment as part of their therapy have virtually the same long-term life experiences as the general population.

    St. Jude researchers use DNA chips to determine how leukemia cells respond to different drug treatments

    Investigators at St. Jude Children's Research Hospital have discovered numerous genes that alter their level of activity in characteristic patterns in response to specific chemotherapy treatments.